News
NeuroSense completed a Phase 2a clinical trial which met its safety and efficacy endpoints including reducing functional and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback